Clinical Trials Logo

Neuralgia clinical trials

View clinical trials related to Neuralgia.

Filter by:

NCT ID: NCT05738096 Recruiting - Clinical trials for Trigeminal Neuralgia

Trigeminal Evoked Responses to Improve Rhizotomy

Start date: November 1, 2023
Phase: Early Phase 1
Study type: Interventional

Trigeminal neuralgia (TGN) is a debilitating pain syndrome where electrical, shock- like jolts of pain affect the face. Trigeminal somatosensory evoked potentials (TSEPs) provide a promising modality for measuring the trigeminal sensory and nociceptive pathway by using peripheral stimulation of the trigeminal nerve (on the skin) and measuring low latency evoked potentials on the scalp (contralateral sensory cortex). While TSEPs have been measured in the past, it is not clear if implementing TSEPs into a routine neurosurgical rhizotomy procedure will be feasible. This is a prospective cohort study examining the feasibility of routinely performing TSEPs during rhizotomies for TGN.

NCT ID: NCT05726929 Recruiting - Breast Cancer Clinical Trials

Algology in Oncology Osteopathic Support (ALGOS)

ALGOS
Start date: January 11, 2023
Phase: N/A
Study type: Interventional

The aim of the study is to evaluate the Impact of add-on osteopathic treatment in the algological course of patients treated for breast cancer : Randomized Controlled Trial.

NCT ID: NCT05701696 Recruiting - Fibromyalgia Clinical Trials

The Relationship Between Neuropathic Complaints and Central Sensitization in Fibromyalgia

Start date: January 16, 2023
Phase:
Study type: Observational

Fibromyalgia (FM) is the prototype of a group of diseases known as central sensitivity syndromes, whose relationship with pain sensitization is well defined. Central sensitization (CS) is also one of the mechanisms involved in the pathophysiology of neuropathic pain. Neuropathic pain, which is a common complaint in FM patients, is likely to be one of the clinical manifestations of central sensitization. Therefore, in this study, it was aimed to investigate the relationship between CS and neuropathic pain.

NCT ID: NCT05685797 Recruiting - Clinical trials for Trigeminal Neuralgia

Biomarker Study in Patients With Trigeminal Neuralgia

Start date: January 25, 2023
Phase: N/A
Study type: Interventional

Investigators performed this study to investigate the expression levels inflammatory cytokine and neurotransmitters (calcitonin gene-related peptide (CGRP), substance P (SP), vasoactive intestinal peptide (VIP), and β-endorphin) in peripheral blood of participants with primary trigeminal neuralgia (TN).

NCT ID: NCT05677243 Recruiting - Clinical trials for Trigeminal Neuralgia

Observational Study on the Treatment of Trigeminal Neuralgia by Radiosurgery

NATURE
Start date: December 15, 2021
Phase:
Study type: Observational [Patient Registry]

This study aims to evaluate the outcome of patient treated by radiosurgery on LINAC with high dose rate for classical trigeminal neuralgia

NCT ID: NCT05674240 Recruiting - Chronic Pain Clinical Trials

Prospective Evaluation of Intrathecal Targeted Drug Delivery for Cancer Associated Pain

Start date: December 6, 2022
Phase:
Study type: Observational [Patient Registry]

This Registry study will prospectively evaluate the differences in treatment outcomes in terms of pain intensity, pain interference, concomitant medication use, health-related quality of life, opioid adverse effects, and healthcare utilization between targeted drug delivery and conservative medication management only groups.

NCT ID: NCT05653778 Recruiting - Pain, Neuropathic Clinical Trials

Scrambler Therapy for Corticobasal Syndrome-Associated Pain

ST-CBS
Start date: April 5, 2024
Phase: N/A
Study type: Interventional

The goal of this pilot trial is to test whether scrambler therapy (ST) is an effective treatment for neuropathic pain in patients with corticobasal syndrome (CBS). The main question it aims to answer is: Will ST reduce pain scores by at least 33% at one month in this pilot trial, justifying further multi-center trials? Participants will: - be randomly assigned treatment from either transcutaneous electrical nerve stimulation (TENS) or ST for pain initially (eventually all patients will receive ST). - have superficial electrocardiogram (ECG) electrodes placed on the dermatomes involved with pain - obtain treatment lasting 30-40 minutes or until pain relief is obtained Researchers will compare patient's response to pain relief with TENS and ST to determine if ST is an effective treatment for central neuropathic pain.

NCT ID: NCT05645003 Recruiting - Clinical trials for Spinal Cord Injuries

Transcranial Magnetic Stimulation Therapy in Neuropathic Painful Spinal Cord Injury Patients

Start date: November 15, 2022
Phase: N/A
Study type: Interventional

The aim of our study is to investigate the effect of high-frequency Repetitive Transcranial Magnetic Stimulation(rTMS) therapy applied to the dorsolateral PFC (DLPFC) area on neuropathic pain in patients with spinal cord injury. In this area, there are very few studies on the effectiveness of rTMS treatment added to medical treatment in neuropathic pain. In addition, the number of studies comparing the effect of rTMS therapy applied to the DLFPC area is very few.

NCT ID: NCT05639946 Recruiting - Clinical trials for Spinal Cord Injuries

Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Start date: January 1, 2023
Phase: Phase 3
Study type: Interventional

Spinal cord injury (SCI) is associated with severe neuropathic pain that is often refractory to pharmacological intervention. Preliminary data suggest brivaracetam is a mechanism-based pharmacological intervention for neuropathic pain in SCI. Based on this and other reports in the literature, SCI-related neuropathic pain is hypothesized to occur largely because of upregulation of synaptic vesicle protein 2A (SV2A) within the substantia gelatinosa of the injured spinal cord. Furthermore, compared to placebo, brivaracetam treatment is hypothesized to reduce severe below-level SCI neuropathic pain and increases parietal operculum (partsOP1/OP4) connectivity strength measured by resting-state functional Magnetic Resonance Imaging (rsfMRI). Circulating miRNA-485 levels may be associated with change in pain intensity due to brivaracetam treatment. The study aims to determine the efficacy of brivaracetam treatment for SCI-related neuropathic pain.

NCT ID: NCT05639322 Recruiting - Neuropathic Pain Clinical Trials

Psychotherapy for Ketamine's Enhanced Durability in Chronic Neuropathic Pain: A Randomized Controlled Pilot Trial

PSYKED-NP
Start date: October 12, 2023
Phase: Phase 4
Study type: Interventional

The purpose of the study is to investigate new therapies to alleviate pain on neuropathic chronic pain. At this time, the main purpose is to complete a feasibility or pilot study with 60 participants suffering from neuropathic chronic pain. Participants will be randomized to (1) Ketamine (Hydrochloride) HCL; (2) psychotherapy (using Cognitive Behavioral Therapy); or (3) a combination of Ketamine HL and psychotherapy.